Delusional disorders are severe psychotic disorders with characteristic non-bizarre delusions often organized in permanent delusional system.AimTo estimate efficacy of risperidone and olanzapine in treatment of DD.Methods135 patients with DD were divided into Haloperidol-control (41), Risperidone (49) and Olanzapine group (45 patients). Patients were observed for 6 months according to protocol, which included PANSS Scale and CGI1-4 Scale. Control group was treated with haloperidol 5–30 mg/24 h. Experimental groups were treated with risperidone 2–6 mg/24 h and olanzapine 10–20 mg/24 h.ResultsPretrial PANSS score was 57.28 in risperidone(R), 60.47 in olanzapine(O) and 58.45 in control(H) group. PANSS score after 180 days was 34.32 in R, 35.58 in O and 37.97 in H group. There was no statistical difference in pretrial scores for PANSS (p = 0.691), CGI1 (p = 0.733), CGI2 (p = 1.000), and CGI3 (p = 1.000) scores. There was statistical significance in PANSS and CGI1-4 score reduction after 180 days in all groups (p = 0.000). There was no statistical difference in PANSS score reduction between R and H (p = 0.114) and O and H group (p = 0.136). CGI1-4 scores reduction: CGI1, Rvs.H, p = 0.019 and Ovs.H, p = 0.032 with high statistical significance; CGI2, Rvs.H, p = 0.153 and Ovs.H, p = 0.179 with no statistical significance; CGI3, Rvs.H, p = 0.183 and Ovs.H, p = 0.161 with no statistical significance; CGI4, Rvs.H, p = 0.000 and Ovs.H, p = 0.000 with high statistical significance. Adverse effects were significantly lower in Risperidone (21.42%) and Olanzapine (21.81%) than in Haloperidol (57.5%) group.ConclusionRisperidone and Olanzapine have slightly better efficacy in treatment of DD comparing to haloperidol, with statisticaly significant lower adverse effects rate.
IntroductionPatients with schizophrenia have elevated rates of cigarette smoking, and difficulty in smoking cessation. Cigarette smoking may reduce plasma levels of antipsychotics up to 50%.ObjectiveTo investigate effects of cigarette smoking in olanzapine treatment of schizophrenia.Methods91 patients with schizophrenia, aged 18-51, were divided into four groups. Control group (25 patients) and experimental groups: E1, 1-20 cigarettes/24h (23 patients), E2, 21-40 cigarettes/24h (22 patients) and E3, 40+ cigarettes/24h (21 patients). Patients were observed for one year period. Patients were assessed by Positive and Negative Symptom Schedule Scale (PANSS) at baseline and after one year.ResultsNo significant differences were found for PANSS score at baseline (p = 0.535). PANSS reduction at study endpoint was significant in all groups (p < 0.001). PANSS reduction was highest in non-smokers group 65.5%, and lowest in group of heavy smokers (40+ cigarettes/24h) 39.2%. There is a statistically significant difference in PANSS reduction between nonsmokers group and all smokers groups (p < 0.001). There is a statistically significant difference in PANSS reduction between E1 and E2, and E1 and E3 group (p < 0.001), and no difference between E2 and E3 group (p = 0.414). There is a statistically significant difference in olanzapine average daily dose after one year between non-smokers group and all smokers groups (p < 0.001).ConclusionsOlanzapine therapy is most efficient in non-smokers group. Smoking more than 20 cigarettes per day significantly reduces effects of olanzapine therapy. Average daily dose of olanzapine is significantly lower in non-smokers group than in all three groups of smokers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.